Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H28N2O5.ClH |
| Molecular Weight | 460.95 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)[C@@H](CCC1=CC=CC=C1)N[C@@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O
InChI
InChIKey=VPSRQEHTHIMDQM-GZJHNZOKSA-N
InChI=1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m1./s1
DescriptionSources: https://www.lgcstandards.com/CN/en/Benazepril-Related-Compound-A/p/USP1048620 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s042lbl.pdfhttps://www.google.com/patents/WO2006084761A1 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s042lbl.pdf | http://usp35.infostar.com.cn/uspnf/pub/data/v35300/usp35nf30s0_m7495.html
Sources: https://www.lgcstandards.com/CN/en/Benazepril-Related-Compound-A/p/USP1048620 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s042lbl.pdfhttps://www.google.com/patents/WO2006084761A1 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s042lbl.pdf | http://usp35.infostar.com.cn/uspnf/pub/data/v35300/usp35nf30s0_m7495.html
BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and also in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.1 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | BENAZEPRIL HYDROCHLORIDE Approved UseBenazepril hydrochloride tablets are indicated for the treatment of hypertension. They
may be used alone or in combination with thiazide diuretics. Launch Date6.777216E11 |
|||
Sample Use Guides
In Vitro Use Guide
Curator's Comment: In the isolated rabbit aorta the vasocontraction induced by PGF2 alpha was competitively antagonized at 10(-5)-10(-4) mol/l, while vascular responses induced by PGE1, PGE2 or PGI2 was inhibited at 3 x 10(-4) mol/l of benazepril. https://www.ncbi.nlm.nih.gov/pubmed/2080946
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID80175881
Created by
admin on Sat Dec 16 07:09:40 UTC 2023 , Edited by admin on Sat Dec 16 07:09:40 UTC 2023
|
PRIMARY | |||
|
56924237
Created by
admin on Sat Dec 16 07:09:40 UTC 2023 , Edited by admin on Sat Dec 16 07:09:40 UTC 2023
|
PRIMARY | |||
|
215447-89-5
Created by
admin on Sat Dec 16 07:09:40 UTC 2023 , Edited by admin on Sat Dec 16 07:09:40 UTC 2023
|
PRIMARY | |||
|
1048620
Created by
admin on Sat Dec 16 07:09:40 UTC 2023 , Edited by admin on Sat Dec 16 07:09:40 UTC 2023
|
PRIMARY | |||
|
ZGK2LDW9PT
Created by
admin on Sat Dec 16 07:09:40 UTC 2023 , Edited by admin on Sat Dec 16 07:09:40 UTC 2023
|
PRIMARY |
SUBSTANCE RECORD
